The global AI-based clinical trials solution provider market size was estimated to be USD 2.00 billion in 2023 and is expected to reach at USD 17.95 billion by 2034 with a CAGR of 22.08% during the forecast period 2024-2034. Growing adoption of AI-based platforms to enhance the productivity and efficiency of trials across different stages, surge in supportive initiatives from both private & public sectors, spanning various therapeutic areas, rising awareness of AI’s diverse applications in clinical trials, growing implementation of AI-based technologies, increasing penetration of AI in drug trials, the availability of AI-based solutions, surge in adoption of technologically advanced solutions for drug discovery, development, & the analysis of recruited patient data, an upswing in research & development activities, rising introduction of cutting-edge AI-based clinical trial platforms are some of the pivotal elements contributing to the expansion of the market.

Rapid Expansion in AI Adoption

The AI-based clinical trials solution provider market is experiencing exponential growth, driven by key advancements in artificial intelligence technology and a surge in AI implementation across therapeutic applications. Projected to escalate at a compound annual growth rate (CAGR) of 22.08% from 2024 to 2034, the market is estimated to grow from USD 2.00 billion in 2023 to a significant USD 17.95 billion by 2034. This expansion is attributed to various factors including a growing need for efficient trial management, enhanced data analysis, and increasing investments in R&D activities within the pharmaceutical industry.

Phenomenal Growth Across Clinical Trial Phases

The Phase-II segment led the market in 2023, supported by a significant number of active phase-II trials and the adoption of AI tools for immediate outcome analysis. Conversely, Phase-I trials are expected to witness the fastest growth rate through the forecast period, as industry stakeholders turn to AI solutions for improved trial design and patient recruitment efforts.

Therapeutic Applications Driving the Market

Oncology remained a top-performing segment in therapeutic applications, owing to the high incidence of cancer globally and the number of AI-integrated clinical trials focused on this domain. Following closely, the cardiovascular disease segment is predicted to grow rapidly, propelled by the increasing prevalence of cardiovascular conditions and the enhanced capability of AI solutions in the analysis of these diseases.

End-User Insights

Pharmaceutical companies constituted the largest end-user segment, leveraging AI to expedite the development of new drugs and enhance diagnostic processes. The sector’s future growth is fortified by industry collaboration and the introduction of sophisticated AI tools targeting various phases of drug development and clinical trials.

Geographical Market Trends

North America holds the leading market share, benefiting from an influx of AI start-ups and strategic initiatives aimed at improving trial outcomes. The Asia Pacific region is anticipated to grow at the most rapid pace, with increasing AI adoption catalyzed by favorable government policies, competitive clinical trial costs, and technological advancements.

This market growth marks a significant milestone in the utilization of AI within healthcare and positions the industry for transformative developments in the years to come. As companies continue to innovate and form strategic alliances, the AI-based clinical trials solution provider market is setting the stage for a new era in drug development and personalized medicine.

This article was originally published by Yahoo Finance. Read the original article here.